Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC)
                     Programmed death-ligand 1 (PD-L1) Non-small Cell Lung Cancer (NSCLC): Overview, 
Epidemiology, Treatment Market, Emerging Drugs and Key players
PD-L1 (also known as CD274) is considered an immune checkpoint is facilitating anti-tumour 
suppression of the immune pathway. 
How has PD-L1 NSCLC impacted people's lives?
 Total cases of Programmed death-ligand 1 (PD-L1) mutated NSCLC in 7MM 
was 242,014 in 2017. 
 Programmed death-ligand 1 (PD-L1) NSCLC cases in the United States in 2017 
was 89,597. 
 Programmed death-ligand 1 (PD-L1) NSCLC cases in Spain in 2017 was 11,585. 
How will Disease transform PD-L1 NSCLC Market? 
Pembrolizumab has received US Food and Drug Administration (FDA) approval for the frontline
treatment of metastatic nonsquamous NSCLC in combination with pemetrexed and carboplatin, 
irrespective of programmed cell death ligand 1 (PD-L1) expression. This combination is the most
preferred treatment option for those with PD-L1 expression